The article discusses the antibiotic resistance of bacterial biofilms, focusing on the mechanisms that contribute to this resistance and the implications for treatment. Biofilms are structured communities of bacteria embedded in a self-produced matrix, which provides protection and allows them to persist in chronic infections. These biofilms are resistant to antibiotics, disinfectants, and the immune system, making them difficult to eradicate. The resistance is due to several factors, including the presence of nutrient and oxygen gradients within the biofilm, which lead to reduced metabolic activity and increased doubling times of bacterial cells. Additionally, biofilms are associated with increased mutation rates and quorum sensing regulated mechanisms, which enhance their ability to survive and adapt. The article highlights that conventional resistance mechanisms such as beta-lactamase production, efflux pumps, and mutations in antibiotic target molecules also contribute to biofilm resistance. Biofilms can be prevented by early aggressive antibiotic prophylaxis or therapy, and they can be treated with chronic suppressive therapy. The use of enzymes that dissolve the biofilm matrix, such as DNase and alginate lyase, and quorum sensing inhibitors can increase the susceptibility of biofilms to antibiotics. The study also discusses the role of hypermutable bacterial strains in biofilms, which are more likely to develop resistance. These strains are associated with increased oxidative stress and mutations in DNA repair systems. The article emphasizes the importance of understanding the complex interactions within biofilms to develop effective treatment strategies. It also highlights the use of quorum sensing inhibitors as a promising strategy to enhance the effectiveness of antibiotics against biofilm infections. The article concludes with a discussion on the management of biofilm infections, particularly in cystic fibrosis patients, and the potential for applying these strategies to other biofilm-related infections.The article discusses the antibiotic resistance of bacterial biofilms, focusing on the mechanisms that contribute to this resistance and the implications for treatment. Biofilms are structured communities of bacteria embedded in a self-produced matrix, which provides protection and allows them to persist in chronic infections. These biofilms are resistant to antibiotics, disinfectants, and the immune system, making them difficult to eradicate. The resistance is due to several factors, including the presence of nutrient and oxygen gradients within the biofilm, which lead to reduced metabolic activity and increased doubling times of bacterial cells. Additionally, biofilms are associated with increased mutation rates and quorum sensing regulated mechanisms, which enhance their ability to survive and adapt. The article highlights that conventional resistance mechanisms such as beta-lactamase production, efflux pumps, and mutations in antibiotic target molecules also contribute to biofilm resistance. Biofilms can be prevented by early aggressive antibiotic prophylaxis or therapy, and they can be treated with chronic suppressive therapy. The use of enzymes that dissolve the biofilm matrix, such as DNase and alginate lyase, and quorum sensing inhibitors can increase the susceptibility of biofilms to antibiotics. The study also discusses the role of hypermutable bacterial strains in biofilms, which are more likely to develop resistance. These strains are associated with increased oxidative stress and mutations in DNA repair systems. The article emphasizes the importance of understanding the complex interactions within biofilms to develop effective treatment strategies. It also highlights the use of quorum sensing inhibitors as a promising strategy to enhance the effectiveness of antibiotics against biofilm infections. The article concludes with a discussion on the management of biofilm infections, particularly in cystic fibrosis patients, and the potential for applying these strategies to other biofilm-related infections.